LAUSR

CRS (Cardio-Renal Metabolic Syndrome) refers to a series of entangled metabolic disorders, including type 2 diabetes, hypertension, hyperlipidemia, chronic kidney disease and heart failure, and is associated with obesity, systemic inflammation, and insulin resistance. Atractylodes lancea (AL) is the rhizome of Atractylodes. AL has been found to have diuretic, sedation, antibacterial, anticancer effects. Therefore, in this study, confirmed the effect of AL on improving cardiovascular and kidney function in the metabolic syndrome model. In this experiment, HFHFr were provided to rats for 8 weeks to induce metabolic syndrome, and the OMT (10 mg/kg/day) or AL (100 or 200 mg/kg/day) were administered orally for 8 weeks with HFHFr for 8 weeks to confirm its efficacy. Therefore, a total of 16 weeks of experiments were conducted. To compare Cont with HFHFr, MS categorys were measured. As a result, AL confirmed that HFHr decreased BW, fasting glucose, TG, and abdominal circumference, systolic blood pressure, and increased HDL-C. As a result of measuring insulin and performing OGTT to confirm insulin resistance, which is a major symptom of MS, AAL ameliorates increased insulin levels, and AAL2 significantly decreased blood glucose levels over time. As a result of confirming echocardiography for cardiac function diagnosis, ejection fraction (EF) and fractional shortening (FS) levels were lower in metabolic syndrome than in the control group and significantly improved in the AAL administration group. Staining to confirm the effect of the heart on fibrosis confirmed that collagen accumulation and fibrosis were increased in HFHFr, and improved by AAL compared to the control group. Therefore, these findings suggest that AL improves obesity, insulin resistance, dyslipidemia, and high blood pressure caused by metabolic syndrome, and has a protective effect on heart function decline and fibrosis of the heart and blood vessels. This study was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (MSIP) (2017R1A5A2015805) (2021R1C1C2095327). This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.